Age group: 6 to 17 years old
Gender: Male or Female
Duration: Up to 52 weeks approximately
Compensation: Up to: $4.050
About the Study:
The purpose of this study is to help us understand the effectiveness of a drug called certolizumab pegol (CZP) in the treatment of moderate to severe chronic plaque or mixed
guttate/plaque psoriasis, how safe it is to use CZP in participants aged 6 to 17 years, and how it works on your child’s general health-related wellbeing. It will also help us understand how CZP acts in the body, how the body reacts to CZP, and the concentration of CZP in the blood (amount of CZP in a given volume of blood) during study treatment.
Who can participate?
Participants must be 6 to 17 years old and have been diagnosed with moderate to severe plaque PSO for > 3 months. Study participants aged > 12 years may alternatively have a diagnosis of moderate to severe mixed guttate/plaque PSO with >50% to <50% guttate lesions for >3 months.
Where is the study taking place?
The study is being conducted at our facility in Palmetto Medical Plaza
NCT04123795
